Statins May Lower Heart Attack and Stroke Risk in Older Adults
A groundbreaking clinical trial conducted by Australian researchers has revealed that a widely used cholesterol-lowering drug, statins, can cut the risk of heart attacks or strokes in individuals aged 70 and above. Importantly, the study indicates that these benefits come with a low likelihood of serious side effects.
Currently, statins are frequently prescribed to individuals under 75 who meet specific risk factors, including conditions like diabetes or elevated cholesterol, to help prevent significant cardiovascular events, such as heart attacks or the need for surgery.
However, until now, it was uncertain whether it was safe to administer daily statins to healthy adults over 70, particularly those who have never had a heart attack, stroke, or surgery, and whether such treatment could effectively prevent future cardiac issues.
Co-author of the study, Adjunct Professor Mark Nelson from Monash University, emphasized the significance of this research. He noted that increasing age is one of the largest risk factors for major heart-related events. “Our society is ageing, and therefore the burden of disease is increasing, making it important to improve our ability to prevent disease in this group,” he remarked. The study aimed to provide the necessary evidence regarding the benefits of statin prescription for this demographic.
Interestingly, older adults were often excluded from early research on statins. This was largely due to the fact that heart disease was predominantly a concern for middle-aged individuals, especially those who smoked. Additionally, elderly populations tend to have multiple health issues and may be on several medications, complicating the testing of new drugs.
To fill this gap, researchers at Monash University evaluated the cardiovascular health of nearly 10,000 participants over 70, who were randomized to receive either daily statins or a placebo. The study was thorough and involved approximately 3,400 general practitioners across Australia.
The researchers did eliminate individuals who had conditions that could make statin use unsafe or those who already required the medication due to a past heart incident.
The decade-long findings showed that statins reduced the risk of initial significant cardiovascular events by 30% for older participants. To put this into perspective, treating 37 older adults with daily statins over nearly six years could prevent one major cardiac event like a heart attack or stroke.
Prof. James Chong, a cardiologist at Westmead Hospital in Sydney, highlighted that if the research results prompt a global increase in statin prescriptions, the overall reduction in heart-related events could be substantial. He also mentioned that the study might help older patients feel more confident about long-term statin use.
That said, he pointed out a key limitation: the study mostly involved a white population with an average age around 75, which may limit the broader applicability of the results without further evidence.
The study results were published in the New England Journal of Medicine over the weekend and also presented at the European Society of Cardiology Congress in Germany.
Lead researcher Adjunct Prof. Sophia Zoungas expressed hope that the strong evidence provided could lead to updated treatment guidelines for clinicians.
It’s advised that older adults discuss the potential benefits of statins with their general practitioners to determine if the medication is suitable for their health.
Prof. Tom Marwick from Hobart’s Royal Hospital remarked on the ongoing misconceptions surrounding statins and their perceived link to dementia, which has deterred many elderly individuals from seeking treatment. The Monash study found no significant difference in dementia rates between those on statins and those who were not, which helps to clarify some of those concerns. He called the study a “well done, really important trial.”
Still, he pointed out some challenges: adherence to the treatment was a concern, with over 15% of trial participants stopping their medication. A bit of disappointment stemmed from the finding that, although major heart events were reduced, the overall quality of life and disability-free survival remained unchanged between those taking statins and those on placebo. Essentially, while cardiovascular events might be less frequent, the broader health issues that come with aging persist.
